| Placebo (N = 28) | Supplement (N = 30) | P4–4b P8–8 | PPlc PSup | ||
---|---|---|---|---|---|---|
% of baseline levels | 4Â week | 8Â week | 4Â week | 8Â week | Â | Â |
LagTime (min)a | 99.9 ± 17.2 | 98.9 ± 12.4 | 96.1 ± 17.1 | 102.2 ± 19.8 |  |  |
Isoprostane (ng/mmol) | 102.7 (83.5–136.1) | 129.8# (100.2–186.9) | 90.3 (58.3–112.1) | 79.0 (45.6–122.9) | 0.05 0.003 | 0.005 0.3 |
oxLDL (μg/mL) | 97.1 (89.0 0–104.4) | 100.5 (87.7–110.0) | 100.3 (91.9–112.5) | 101.7 (89.2–112.1) | 0.5 0.1 | 0.2 0.8 |
TBARS (μΜ)a | 107.1 ± 27.4 | 100.3 ± 25.5 | 100.0 ± 26.7 | 104.3 ± 31.8 |  |  |
8-hydroxy-2΄-deoxyguanosine (μg/mmol) | 96.1 (83.8–128.8) | 102.8 (88.9–145.2) | 85.2,# (60.9–101.8) | 72.3# (45.2–102.6) | 0.02 0.000 | 0.4 0.003 |
Protein Carbonyls (nmol/mg protein) | 112.8 (91.6–120.5) | 104.5 (91.5–118.1) | 83.3# (71.7–102.3) | 81.3# (61.7–100.6) | 0.000 0.001 | 0.3 0.003 |
Gpx activity (U/mL) | 95.8 (87.6–116.7) | 94.7 (74.8–115.4) | 100.0 (87.6–115.3) | 102.9 (88.2–117.5) | 0.8 0.1 | 0.3 0.9 |
SOD activity (U/mg protein) | 106.4 (75.0–160.4) | 88.1 (66.7–151).7 | 63.6# |(42.8–127.4) | 71.3 (50.4–126.8) | 0.01 0.2 | 0.7 0.008 |